恶性心周溢血的心内白血素:重新审视一个向的药理学方法
Danny L Rayes1, Hira Latif2, Syed Waqas Haider3
1Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC, USA.
Journal of cardiovascular pharmacology
|July 29, 2025
概括
恶性心周溢液的管理可以通过白素改善,白素是一种硬化剂. 这种治疗效果与手术类似,但对于晚期癌症患者来说,耐受性更好.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 抚慰性护理是一种缓解性护理.
背景情况:
- 恶性心周溢出是晚期癌症的严重并发症,经常导致心脏坦波纳德.
- 由于复发率高,治疗很困难,手术和排水有局限性.
研究的目的:
- 评估白素作为恶性心周流的有效和耐受性治疗方法.
- 为了比较白素的疗效和耐受性与传统的管理选择.
主要方法:
- 关于恶性心周溢液管理的当前文献的综述.
- 分析最近关于白素作为腹膜内硬化剂的使用证据.
主要成果:
- 布莱米辛的疗效与外科手术心周窗口和导管排水相提并论.
- 与其他硬化剂相比,白素具有更好的耐受性,并且与手术相比降低了病率.
结论:
- 布莱米是一种有前途的缓解性选择,用于恶性心周溢血.
- 它的疗效和良好的耐受性概况支持在临床实践中更广泛地采用.
相关概念视频
Pericarditis III: Medical Management
26
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
26
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
44
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
44
Pleural Effusion II: Symptoms and Management
272
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
272
Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Pericarditis IV: Nursing Management
54
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
54
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
259
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
259


